Samuel Wright

Samuel Wright

Global Director for Cardiovascular Therapeutics, CSL Research and Development

Samuel D. Wright joined CSL in 2008 with a primary commitment to the development of CSL112, a novel therapy for acute coronary syndrome. Prior to joining CSL, Dr. Wright served as Vice President and Worldwide Basic Research Head for Cardiovascular Disease Merck Research Laboratories. Dr. Wright received his PhD from Harvard University in Cambridge Massachusetts in 1979. His postdoctoral work was followed by appointments of Assistant Professor and Associate Professor at The Rockefeller University in New York City. He is the author of over 185 original research papers as well as numerous reviews and chapters and is listed as a highly cited author in Immunology by the Institute of Scientific Information.

CSL 112 as a tool to understand remodeling and HDL functionality